EBITDA grew 14.8 per cent YoY to Rs 2,181 million
Strides Pharma Science announced its consolidated financial results for the quarter (Q1FY26) ended June 30, 2025.
Q1FY2026 Performance Highlights
§ Revenue at Rs 11,197 million, grew 6.2 per cent YoY
§ Absolute gross margin at Rs 6,755 million, grew 11.7% YoY
§ Gross margin improved to 60.3 per cent, up 300bps YoY
§ EBITDA grew 14.8 per cent YoY to Rs 2,181 million with EBITDA margin at 19.5 per cent, grew 150bps YoY
§ US revenue at $71 million, grew 7 per cent YoY
§ Operational PAT at Rs 1,140 million, Grew 80.6 per cent YoY
§ Operational EPS at Rs 12.4
§ Reported PAT at Rs 1,056 million
Badree Komandur, MD and Group CEO, Strides Pharma Science said, “We are pleased to report a solid start to the year, marked by consistent growth and enhanced profitability. Our focus on cost management and diligent execution has enabled us to deliver robust results. The EBITDA margin improved to 19.5 per cent, an increase of 150bps YoY. Strong operating leverage contributed to the highest-ever quarterly PAT, resulting in an operational EPS of Rs 12.4. Consequently, ROCE stands at 15.1 per cent for Q1. The company will enhance its R&D efforts during the year to drive sustainable long-term growth.”
